Singapore: AB SCIEX, a global leader in life science analytical technologies, announced a global initiative focused on biologics. This new initiative is in response to the fundamental shift of the pharmaceutical industry into biopharmaceutical development.

AB SCIEX's BiologicsFocus Initiative consists of four components, including new product development; beta software evaluation program; one-on-one connections program; and forums for sharing the latest advancements in biologics across the scientific community. The company revealed this initiative at the International Mass Spectrometry Conference (IMSC) in Japan.

The BiologicsFocus Initiative represents AB SCIEX's open approach to producing comprehensive biologics solutions by involving scientists in industry and academia in the development of new tools. AB SCIEX already has a proven track record with its TripleTOF technology for bio-therapeutics characterization. The company is now taking the next important step to address an industry-wide need - the development of data analysis solutions to simplify and accelerate biologics development.

The trend is to transition away from the traditional model of drug development, which is based on small molecule analysis. The promise of biopharmaceuticals is that pharmaceutical companies will be able to more rapidly develop more effective drugs with fewer side effects. Recent advancements in technologies for large molecule analysis, such as protein characterization, have sped up the shift to bio-therapeutics.

AB SCIEX's biologics initiative includes the programs such as BiologicsFocus Innovation, BiologicsFocus Eval, BiologicsFocus Summits, and BiologicsFocus Connections.